(Cancer of Unknown Primary) Is Opdivo Effective?
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- December 13, 2021
- 1 min read
On November 26, 2021, Dr. Junko Tanizaki and colleagues from Kindai University Faculty of Medicine published results in Annals of Oncology from the NivoCUP Phase 2 clinical trial evaluating the efficacy and safety of the anti-PD-1 antibody Opdivo (nivolumab) in cancer of unknown primary (CUP) patients.
This multi-center, single-arm Phase 2 trial administered Opdivo (240 mg every 2 weeks, up to 52 cycles) to CUP patients (N=56), with objective response rate (ORR) as the primary endpoint. Of these patients, 45 had received one prior line of therapy.
The trial was initiated because CUP carries a poor prognosis, and immune checkpoint inhibitors have demonstrated efficacy across multiple cancer types. The study aimed to evaluate the therapeutic value of nivolumab in this difficult-to-treat population.
Results (in patients with prior treatment, N=45):
- Objective response rate (ORR): 22.2%
- Median progression-free survival (PFS): 4.0 months
- Median overall survival (OS): 15.9 months
Safety: The safety profile was consistent with existing nivolumab clinical trial data. No treatment-related deaths were reported.
Conclusion: Based on the NivoCUP trial results, Dr. Tanizaki and colleagues concluded that Opdivo demonstrated promising anti-tumor activity in CUP patients, potentially representing a new treatment option for this population.
Source: https://www.annalsofoncology.org/article/S0923-7534(21)04824-9/fulltext
-
Immunotherapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4